Intraperitoneal Chemotherapy Following Refractory Intravenous Route in Advanced Ovarian Cancer
- Author:
Shafiee MN
;
Omar MH
;
Suraya A
;
Hatta M
- Publication Type:Case Reports
- Keywords:
Adjuvant;
chemotherapy;
cisplatin;
intraperitoneal;
ovarian cancer
- From:Journal of Surgical Academia
2013;3(1):28-31
- CountryMalaysia
- Language:English
-
Abstract:
Platinum based adjuvant chemotherapy is generally recommended for ovarian cancer to improve the survival rate.
Intravenous route is commonly used, easily administered and less associated complications. However, intraperitoneal
route is gaining its popularity as a single procedure or adjunctive to the intravenous route. Numerous questions on its
eligibility and safety are still perplexed. A case review on a patient with non optimal debulking surgery of advanced
ovarian cancer was studied. Intravenous platinum based chemotherapy combined with paclitaxel failed to bring her
to clinical remission. Second line chemotherapy, gemcitabin rendered her to poor response with unresolved
debilitating ascites needing recurrent drainage. Surprisingly, a trial of intraperitoneal chemotherapy with cisplatin
revealed a great response with a complete clinical remission.
- Full text:P020150615473812000599.pdf
